Patents by Inventor Joyce Tombran-Tink

Joyce Tombran-Tink has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EPIGENETIC MODIFIERS TO TREAT RETINAL DEGENERATIONS
    Publication number: 20230310542
    Abstract: The present disclosure relates to the prevention and/or treatment of retinal degeneration using epigenetic modifying agents and their uses thereof.
    Type: Application
    Filed: April 4, 2023
    Publication date: October 5, 2023
    Inventors: Colin J. Barnstable, Evgenya Y. Popova, Joyce Tombran-Tink
  • Functional Peptide Analogs of PEDF
    Publication number: 20170253646
    Abstract: The invention provides compositions and methods relating to bioactive peptide analogs of PEDF.
    Type: Application
    Filed: April 3, 2017
    Publication date: September 7, 2017
    Inventors: Joyce Tombran-Tink, Colin J. Barnstable
  • Functional peptide analogs of PEDF
    Patent number: 9611314
    Abstract: The invention provides compositions and methods relating to bioactive peptide analogs of PEDF.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: April 4, 2017
    Assignee: The Penn State Research Foundation
    Inventors: Joyce Tombran-Tink, Colin J. Barnstable
  • Functional Peptide Analogs of PEDF
    Publication number: 20150079094
    Abstract: The invention provides compositions and methods relating to bioactive peptide analogs of PEDF.
    Type: Application
    Filed: September 12, 2014
    Publication date: March 19, 2015
    Inventors: Joyce Tombran-Tink, Colin J. Barnstable
  • Retinal pigmented epithelium derived neurotrophic factor
    Patent number: 7511009
    Abstract: The present invention relates to a purified retinal pigmented epithelium derived neurotrophic factor composition and a method for purifying such a retinal pigmented epithelium neurotrophic factor. The present invention also relates to a recombinant DNA molecule comprising a gene encoding a retinal pigmented epithelium derived neurotrophic factor having the DNA sequence or the amino acid sequence in SEQ ID NO:1 and to an organism transformed with the recombinant DNA molecule. In addition, the present invention relates to a method of treating tumors, ocular diseases, nerve injuries, and conditions resulting from the activity of serine proteases, which comprises administering PEDF.
    Type: Grant
    Filed: August 9, 2002
    Date of Patent: March 31, 2009
    Assignee: The National Institutes of Health
    Inventors: Joyce Tombran-Tink, Gerald J. Chader, Sofia Patricia Becerra, Ignacio R. Rodriguez, Fintan R. Steele, Lincoln V. Johnson
  • Compositions and Methods for Use of Pigment Epithelial Derived Factor (PEDF) Peptide Fragments
    Publication number: 20090069241
    Abstract: The invention provides PEDF peptides which retain the biological activity of full-length PEDF. Fusion proteins comprising a PEDF peptide are also provided. The invention further provides a codon-optimized PEDF coding sequence and method of expressing it in bacteria. Compositions, methods of use and kits are also provided.
    Type: Application
    Filed: February 15, 2007
    Publication date: March 12, 2009
    Applicants: Yale University, The Curators of the University of Missouri
    Inventors: Colin J Barnstable, Joyce Tombran-Tink
  • Retinal pigmented epithelium derived neurotrophic factor
    Publication number: 20070281886
    Abstract: The present invention relates to a purified retinal pigmented epithelium derived neurotrophic factor composition and a method for purifying such a retinal pigmented epithelium neurotrophic factor. The present invention also relates to a recombinant DNA molecule comprising a gene encoding a retinal pigmented epithelium derived neurotrophic factor having the DNA sequence or the amino acid sequence in SEQ ID NO:1 and to an organism transformed with the recombinant DNA molecule. In addition, the present invention relates to a method of treating tumors, ocular diseases, nerve injuries, and conditions resulting from the activity of serine proteases, which comprises administering PEDF.
    Type: Application
    Filed: August 9, 2002
    Publication date: December 6, 2007
    Inventors: Joyce Tombran-Tink, Fintan Steele, Gerald Chader, Sofia Becerra, Lincoln Johnson, Ignacio Rodriguez
  • Pigment epithelium-derived factor: sequence of the PEDF gene
    Patent number: 7179621
    Abstract: Nucleic acids encoding the neurotrophic protein known as pigment epithelium derived factor (PEDF), a truncated version of PEDF referred to as rPEDF, and equivalent proteins, vectors comprising such nucleic acids, host cells into which such vectors have been introduced, recombinant methods for producing PEDF, rPEDF, and equivalent proteins, the rPEDF protein and equivalent proteins of rPEDF and PEDF-BP, -BX and BA, and the PEDF protein produced by recombinant methods. Effects and uses of these variants on 1) neuronal differentiation (neurotrophic effect) 2) neuron survival (neuronotrophic effect) and 3) glial inhibition (gliastatic effect) are described.
    Type: Grant
    Filed: August 1, 2000
    Date of Patent: February 20, 2007
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Gerald J. Chader, Ignacio R. Rodriguez, Joyce Tombran-Tink, Sofia Patricia Becerra, Fintan R. Steele, Lincoln V. Johnson
  • Pigment epithelium-derived factor: characterization, genomic organization and sequence of the PEDF gene
    Publication number: 20060008900
    Abstract: Nucleic acids encoding the neurotrophic protein known as pigment epithelium-derived factor (PEDF), a truncated version of PEDF referred to as rPEDF, and equivalent proteins, vectors comprising such nucleic acids, host cells into which such vectors have been introduced, recombinant methods for producing PEDF, rPEDF, and equivalent proteins, the rPEDF protein and equivalent proteins of rPEDF and PEDF-BP, -BX and BA, and the PEDF protein produced by recombinant methods. Effects and uses of these variants on 1) neuronal differentiation (neurotrophic effect) 2) neuron survival (neuronotrophic effect) and 3) glial inhibition (gliastatic effect) are described.
    Type: Application
    Filed: August 10, 2005
    Publication date: January 12, 2006
    Applicant: The United States of America, As Represented by the Dept. of Health and Human Services
    Inventors: Gerald Chader, Ignacio Rodriguez, Joyce Tombran-Tink, Sofia Becerra, Fintan Steele, Lincoln Johnson
  • Retinal pigmented epithelium derived neurotrophic factor
    Publication number: 20030096750
    Abstract: The present invention relates to a purified retinal pigmented epithelium derived neurotrophic factor composition and a method for purifying such a retinal pigmented epithelium neurotrophic factor. The present invention also relates to a recombinant DNA molecule comprising a gene encoding a retinal pigmented epithelium derived neurotrophic factor having the DNA sequence or the amino acid sequence in SEQ ID NO:1 and to an organism transformed with the recombinant DNA molecule.
    Type: Application
    Filed: August 9, 2002
    Publication date: May 22, 2003
    Inventors: Joyce Tombran-Tink, Fintan R. Steele, Gerald J. Chader, Sofia Patricia Becerra, Lincoln V. Johnson, Ignacio R. Rodriguez
  • Retinal pigmented epithelium derived neurotrophic factor and methods of use
    Patent number: 6451763
    Abstract: The present invention relates to a purified retinal pigmented epithelium derived neurotrophic factor composition and a method for purifying such a retinal pigmented epithelium neurotrophic factor. The present invention also relates to a recombinant DNA molecule comprising a gene encoding a retinal pigmented epithelium derived neurotrophic factor having the DNA sequence or the amino acid sequence in SEQ ID NO:1 and to an organism transformed with the recombinant DNA molecule. In addition, the present invention relates to a method of treating tumors, ocular diseases, nerve injuries, and conditions resulting from the activity of serine proteases, which comprises administering PEDF.
    Type: Grant
    Filed: August 29, 1995
    Date of Patent: September 17, 2002
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Joyce Tombran-Tink, Gerald J. Chader, Sofia Patricia Becerra, Ignacio R. Rodriguez, Fintan R. Steele, Lincoln V. Johnson
  • Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene
    Patent number: 6319687
    Abstract: Nucleic acids encoding the neurotrophic protein known as pigment epithelium-derived factor (PEDF), a truncated version of PEDF referred to as rPEDF, and equivalent proteins, vectors comprising such nucleic acids, host cells into which such vectors have been introduced, recombinant methods for producing PEDF, rPEDF, and equivalent proteins, the rPEDF protein and equivalent proteins of rPEDF and PEDF-BP, -BX and BA, and the PEDF protein produced by recombinant methods. Effects and uses of these variants on 1) neuronal differentiation (neurotrophic effect) 2) neuron survival (neuronotrophic effect) and 3) glial inhibition (gliastatic effect) are described.
    Type: Grant
    Filed: December 30, 1994
    Date of Patent: November 20, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Gerald J. Chader, S. Patricia Becerra, Joyce Tombran-Tink, Lincoln V. Johnson, Fintan R. Steele, Ignacio Rodriguez